标题
The immune modifying effects of chemotherapy and advances in chemo-immunotherapy
作者
关键词
-
出版物
PHARMACOLOGY & THERAPEUTICS
Volume 236, Issue -, Pages 108111
出版商
Elsevier BV
发表日期
2022-01-10
DOI
10.1016/j.pharmthera.2022.108111
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Neoadjuvant chemotherapy induces IL-34 signaling and promotes chemoresistance via tumor-associated macrophage polarization in esophageal squamous cell carcinoma
- (2021) Shotaro Nakajima et al. MOLECULAR CANCER RESEARCH
- Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
- (2021) Davide Melisi et al. Journal for ImmunoTherapy of Cancer
- Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response
- (2021) Floris Dammeijer et al. EBioMedicine
- Trials and tribulations of pancreatic cancer immunotherapy
- (2021) Daniel R. Principe et al. CANCER LETTERS
- Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial
- (2021) Keunchil Park et al. Journal of Thoracic Oncology
- Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
- (2021) Nancy Y Lee et al. LANCET ONCOLOGY
- Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors
- (2021) Inken Salewski et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study.
- (2021) Yelena Y. Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
- (2021) Jong-Mu Sun et al. LANCET
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
- (2021) Yelena Y Janjigian et al. LANCET
- Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
- (2021) Thomas Powles et al. LANCET ONCOLOGY
- Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
- (2021) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
- (2021) Bradley J Monk et al. LANCET ONCOLOGY
- T Cell–Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer
- (2021) Dandan Li et al. MOLECULAR CANCER THERAPEUTICS
- Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer
- (2020) S. Adams et al. ANNALS OF ONCOLOGY
- NK cells for cancer immunotherapy
- (2020) Noriko Shimasaki et al. NATURE REVIEWS DRUG DISCOVERY
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resistance to Checkpoint Inhibition in Cancer Immunotherapy
- (2020) Luisa Barrueto et al. Translational Oncology
- Low-Dose Gemcitabine Treatment Enhances Immunogenicity and Natural Killer Cell-Driven Tumor Immunity in Lung Cancer
- (2020) Xin Zhang et al. Frontiers in Immunology
- Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
- (2020) R.L. Ferris et al. ANNALS OF ONCOLOGY
- Changes in Tumor-infiltrating Lymphocytes After Neoadjuvant Chemotherapy and Clinical Significance in Triple Negative Breast Cancer
- (2020) HYUN LEE et al. ANTICANCER RESEARCH
- Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy
- (2020) Daniel R Principe et al. CANCER RESEARCH
- Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
- (2020) Matthew D Galsky et al. LANCET
- Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
- (2020) Jing Huang et al. LANCET ONCOLOGY
- FOLFOX Chemotherapy Ameliorates CD8 T Lymphocyte Exhaustion and Enhances Checkpoint Blockade Efficacy in Colorectal Cancer
- (2020) Yue Guan et al. Frontiers in Oncology
- Tumor-infiltrating Lymphocyte Score Based on FDG PET/CT for Predicting the Effect of Neoadjuvant Chemotherapy in Breast Cancer
- (2020) SHINSUKE SASADA et al. ANTICANCER RESEARCH
- Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells
- (2020) P. L. Smith et al. Clinical & Translational Oncology
- A decade of immune-checkpoint inhibitors in cancer therapy
- (2020) Caroline Robert Nature Communications
- Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
- (2020) Takashi Kojima et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
- (2020) Elizabeth A Mittendorf et al. LANCET
- Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
- (2020) Kohei Shitara et al. JAMA Oncology
- The outstanding antitumor capacity of CD4+ T helper lymphocytes
- (2020) Tong Li et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
- (2020) Caicun Zhou et al. Lancet Respiratory Medicine
- Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer
- (2020) Emese Zsiros et al. JAMA Oncology
- Induction of peripheral effector CD8 T cell proliferation by combination of paclitaxel, carboplatin and bevacizumab in non-small cell lung cancer patients
- (2019) Pauline L de Goeje et al. CLINICAL CANCER RESEARCH
- Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor
- (2019) Allison Gartung et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?
- (2019) Christine Ménétrier-Caux et al. Journal for ImmunoTherapy of Cancer
- Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial
- (2019) Hyun Cheol Chung et al. Journal for ImmunoTherapy of Cancer
- Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
- (2019) Martin Reck et al. Lancet Respiratory Medicine
- Oxaliplatin Treatment Alters Systemic Immune Responses
- (2019) Vanesa Stojanovska et al. Biomed Research International
- Phase I study of nivolumab (Nivo) + nab-paclitaxel (nab-P) + gemcitabine (Gem) in advanced pancreatic cancer (APC).
- (2019) Zev A. Wainberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study
- (2019) U A Matulonis et al. ANNALS OF ONCOLOGY
- Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade
- (2019) DAIKO WAKITA et al. ANTICANCER RESEARCH
- Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer
- (2019) Lei Guo et al. JOURNAL OF IMMUNOTHERAPY
- Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
- (2019) Howard West et al. LANCET ONCOLOGY
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
- (2019) Filipe Martins et al. Nature Reviews Clinical Oncology
- Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Esophageal Squamous Cell Carcinoma
- (2019) EIJI FUKUOKA et al. ANTICANCER RESEARCH
- Emerging strategies in cancer therapy combining chemotherapy with immunotherapy
- (2019) Qiuhua Luo et al. CANCER LETTERS
- Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
- (2019) Robert L. Ferris et al. CLINICAL CANCER RESEARCH
- Immunogenic cell death in cancer therapy: Present and emerging inducers
- (2019) Jingyi Zhou et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer
- (2019) James W. Opzoomer et al. Frontiers in Immunology
- Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
- (2019) Alfonso Serrano-del Valle et al. Frontiers in Cell and Developmental Biology
- The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy
- (2019) David A. Schaer et al. CLINICAL CANCER RESEARCH
- CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin
- (2019) Jeanne Galaine et al. INTERNATIONAL JOURNAL OF CANCER
- Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer
- (2019) So-Jin Park et al. ORAL ONCOLOGY
- Neoadjuvant cisplatin and paclitaxel modulate tumor-infiltrating T cells in patients with cervical cancer
- (2019) A. Marijne Heeren et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
- (2019) Luis Paz-Ares et al. LANCET
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study
- (2019) Suneel D. Kamath et al. ONCOLOGIST
- Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination
- (2019) Yosi Gilad et al. Scientific Reports
- Clinical significance of tumor-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in patients with stage III colon cancer who underwent surgery followed by FOLFOX chemotherapy
- (2019) Yoon Jin Cha et al. Scientific Reports
- Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
- (2019) Satya Das et al. Journal for ImmunoTherapy of Cancer
- Platinum Derivatives Effects on Anticancer Immune Response
- (2019) Cédric Rébé et al. Biomolecules
- Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer
- (2018) Erta Kalanxhi et al. BRITISH JOURNAL OF CANCER
- Impact of 5-Fu/oxaliplatin on mouse dendritic cells and synergetic effect with a colon cancer vaccine
- (2018) Xinqiang Hong et al. Chinese Journal of Cancer Research
- Docetaxel promotes the generation of anti-tumorigenic human macrophages
- (2018) Camilla Rydberg Millrud et al. EXPERIMENTAL CELL RESEARCH
- T-cell modulation by cyclophosphamide for tumour therapy
- (2018) Ellyn Hughes et al. IMMUNOLOGY
- Safety and Antitumor Activity of the Anti–Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma
- (2018) Toshihiko Doi et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine directly inhibits effector CD4 T cell activation and prevents experimental autoimmune encephalomyelitis
- (2018) Justin D. Glenn et al. JOURNAL OF NEUROIMMUNOLOGY
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- (2018) Thomas Powles et al. LANCET
- Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
- (2018) Manish R Patel et al. LANCET ONCOLOGY
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cyclophosphamide-modified murine peritoneal macrophages induce CD4 + T contrasuppressor cells that protect contact sensitivity T effector cells from suppression
- (2018) Monika Majewska-Szczepanik et al. Pharmacological Reports
- Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells
- (2018) A. M. Gravett et al. OncoImmunology
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
- (2018) Yelena Y. Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
- (2018) Fabrice Barlesi et al. LANCET ONCOLOGY
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chemotherapeutic Treatments Increase PD-L1 Expression in Esophageal Squamous Cell Carcinoma through EGFR/ERK Activation
- (2018) Hoi Yan Ng et al. Translational Oncology
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Gemcitabine treatment promotes immunosuppressive microenvironment in pancreatic tumors by supporting the infiltration, growth, and polarization of macrophages
- (2018) Sachin Kumar Deshmukh et al. Scientific Reports
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
- (2018) Ezra E W Cohen et al. LANCET
- TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell Mediated Regression of Pancreatic Cancer
- (2018) Daniel R Principe et al. MOLECULAR CANCER THERAPEUTICS
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles
- (2018) Shannon Grabosch et al. ONCOGENE
- Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer
- (2018) Junghoon Shin et al. Cancer Research and Treatment
- Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus
- (2018) Manish A. Shah et al. JAMA Oncology
- RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer
- (2018) Fanny Ledys et al. Journal for ImmunoTherapy of Cancer
- Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
- (2017) Glen J. Weiss et al. INVESTIGATIONAL NEW DRUGS
- Phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) ± gemcitabine (Gem) in solid tumors: Interim results from the pancreatic cancer (PC) cohorts.
- (2017) Zev A. Wainberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial.
- (2017) Yoon-Koo Kang et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase Ib/II pilot trial with nab-paclitaxel plus gemcitabine plus cisplatin in patients (pts) with stage IV pancreatic cancer.
- (2017) Gayle S. Jameson et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
- (2017) Joshua Bauml et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Yoon-Koo Kang et al. LANCET
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
- (2017) Toshihiro Kudo et al. LANCET ONCOLOGY
- Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
- (2017) James L Gulley et al. LANCET ONCOLOGY
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
- (2017) Arjun V Balar et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy
- (2017) Reza Nejati et al. PANCREAS
- Dysregulation of cytokine mediated chemotherapy induced cognitive impairment
- (2017) Xiaojia Ren et al. PHARMACOLOGICAL RESEARCH
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism
- (2017) George S. Karagiannis et al. Science Translational Medicine
- Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma
- (2017) Linda Tran et al. Cancer Immunology Research
- Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance
- (2017) Derek W. Edwardson et al. PLoS One
- MHC class I chain-related molecule A and B expression is upregulated by cisplatin and associated with good prognosis in patients with non-small cell lung cancer
- (2016) Riki Okita et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells
- (2016) E. Beyranvand Nejad et al. CANCER RESEARCH
- Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy
- (2016) Charlotte S. Lo et al. CLINICAL CANCER RESEARCH
- Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- (2016) Naiyer A. Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer
- (2016) Emma Eriksson et al. Journal of Translational Medicine
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- (2016) Corey J Langer et al. LANCET ONCOLOGY
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis
- (2016) Ke Wang et al. Oncotarget
- Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study†
- (2015) Y. T. Cheung et al. ANNALS OF ONCOLOGY
- STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells
- (2015) Heng Yang et al. CANCER RESEARCH
- Suppressive effects of gemcitabine plus cisplatin chemotherapy on regulatory T cells in nonsmall-cell lung cancer
- (2015) Cheng Chen et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors
- (2015) Stuart A. Grossman et al. Journal of the National Comprehensive Cancer Network
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells
- (2015) Riki Okita et al. PLoS One
- Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy
- (2015) Jennifer A. Wargo et al. SEMINARS IN ONCOLOGY
- A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer
- (2014) M. Aglietta et al. ANNALS OF ONCOLOGY
- Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy
- (2014) Christian P. Pallasch et al. CELL
- Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence
- (2014) A. R. de Biasi et al. CLINICAL CANCER RESEARCH
- Gemcitabine-treated pancreatic cancer cell medium induces the specific CTL antitumor activity by stimulating the maturation of dendritic cells
- (2014) Qingshan Pei et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
- (2014) Antonella Sistigu et al. NATURE MEDICINE
- Influence of cyclophosphamide and its metabolic products on the activity of peritoneal macrophages in mice
- (2014) Krzysztof Bryniarski et al. Pharmacological Reports
- Chemotherapy Enhances Cross-Presentation of Nuclear Tumor Antigens
- (2014) Chidozie C. Anyaegbu et al. PLoS One
- Selective Depletion of Regulatory T Cell Subsets by Docetaxel Treatment in Patients with Nonsmall Cell Lung Cancer
- (2014) Jie-Yao Li et al. Journal of Immunology Research
- Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set
- (2014) Abdul Qader Sukkurwala et al. OncoImmunology
- Chemotherapy Alters Monocyte Differentiation to Favor Generation of Cancer-Supporting M2 Macrophages in the Tumor Microenvironment
- (2013) E. M. Dijkgraaf et al. CANCER RESEARCH
- Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
- (2013) L Bracci et al. CELL DEATH AND DIFFERENTIATION
- Inducers of immunogenic cancer cell death
- (2013) Aleksandra M. Dudek et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Human CD4+CD25+ Regulatory T Cells Are Sensitive to Low Dose Cyclophosphamide: Implications for the Immune Response
- (2013) Daniel Heylmann et al. PLoS One
- Effects of conventional therapeutic interventions on the number and function of regulatory T cells
- (2013) Mario Roselli et al. OncoImmunology
- Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death
- (2012) Isabelle Martins et al. Autophagy
- Defining the Molecular Signature of Chemotherapy-Mediated Lung Tumor Phenotype Modulation and Increased Susceptibility to T-Cell Killing
- (2012) Sofia R. Gameiro et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8+ T cells in vivo
- (2012) Connie Jackaman et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice
- (2012) Alexandra Sevko et al. Journal of Immunotoxicology
- The Immunological Impact of Neoadjuvant Chemotherapy on the Tumor Microenvironment of Esophageal Squamous Cell Carcinoma
- (2011) Takahiro Tsuchikawa et al. ANNALS OF SURGICAL ONCOLOGY
- Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer
- (2011) Makiko Ono et al. BREAST CANCER RESEARCH AND TREATMENT
- The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues
- (2011) Jurjen Tel et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Chemotherapy Induces Intratumoral Expression of Chemokines in Cutaneous Melanoma, Favoring T-cell Infiltration and Tumor Control
- (2011) M. Hong et al. CANCER RESEARCH
- A reduction of recipient regulatory T cells by cyclophosphamide contributes to an anti-tumor effect of nonmyeloablative allogeneic stem cell transplantation in mice
- (2011) Ario Takeuchi et al. INTERNATIONAL JOURNAL OF CANCER
- In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival
- (2011) Sylvain Ladoire et al. JOURNAL OF PATHOLOGY
- Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy
- (2011) Ioannis Alagkiozidis et al. Journal of Translational Medicine
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
- (2011) M. Michaud et al. SCIENCE
- Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs
- (2010) T. Nakahara et al. BLOOD
- Differential effects of Paclitaxel on dendritic cell function
- (2010) Justin John et al. BMC IMMUNOLOGY
- Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice
- (2010) Lukas W. Pfannenstiel et al. CELLULAR IMMUNOLOGY
- A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers
- (2010) K. N. Kodumudi et al. CLINICAL CANCER RESEARCH
- Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages
- (2010) Ilia N. Buhtoiarov et al. IMMUNOLOGY
- Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells
- (2010) Lorna Rettig et al. INTERNATIONAL JOURNAL OF CANCER
- Cyclophosphamide Induces Dynamic Alterations in the Host Microenvironments Resulting in a Flt3 Ligand-Dependent Expansion of Dendritic Cells
- (2010) Mohamed L. Salem et al. JOURNAL OF IMMUNOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress
- (2010) I Martins et al. ONCOGENE
- Immune Response During Therapy With Cisplatin or Radiation for Human Papillomavirus–Related Head and Neck Cancer
- (2009) William C. Spanos et al. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY
- Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy
- (2009) M Shehata et al. BRITISH JOURNAL OF CANCER
- Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
- (2009) W M Liu et al. BRITISH JOURNAL OF CANCER
- Regular Dose of Gemcitabine Induces an Increase in CD14+ Monocytes and CD11c+ Dendritic Cells in Patients with Advanced Pancreatic Cancer
- (2009) Atsuko Soeda et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation
- (2009) Leisha A. Emens et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2009) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism
- (2009) G. V. Shurin et al. JOURNAL OF IMMUNOLOGY
- Recovery from Cyclophosphamide-Induced Lymphopenia Results in Expansion of Immature Dendritic Cells Which Can Mediate Enhanced Prime-Boost Vaccination Antitumor Responses In Vivo When Stimulated with the TLR3 Agonist Poly(I:C)
- (2009) M. L. Salem et al. JOURNAL OF IMMUNOLOGY
- Administration of Cyclophosphamide Changes the Immune Profile of Tumor-bearing Mice
- (2009) Pu Liu et al. JOURNAL OF IMMUNOTHERAPY
- Secondary fibrosarcoma of the brain stem treated with cyclophosphamide and Imatinib
- (2009) Daniela Alexandru et al. JOURNAL OF NEURO-ONCOLOGY
- Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations
- (2009) Ramon Kaneno et al. Journal of Translational Medicine
- Immunogenic death of colon cancer cells treated with oxaliplatin
- (2009) A Tesniere et al. ONCOGENE
- Tumor-Infiltrating Lymphocytes and Perforation in Colon Cancer Predict Positive Response to 5-Fluorouracil Chemotherapy
- (2008) M. Morris et al. CLINICAL CANCER RESEARCH
- Allogeneic Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation
- (2008) D. Laheru et al. CLINICAL CANCER RESEARCH
- Pretreatment with Cisplatin Enhances E7-Specific CD8+ T-Cell-Mediated Antitumor Immunity Induced by DNA Vaccination
- (2008) C.-W. Tseng et al. CLINICAL CANCER RESEARCH
- Cisplatin primes murine peritoneal macrophages for enhanced expression of nitric oxide, proinflammatory cytokines, TLRs, transcription factors and activation of MAP kinases upon co-incubation with L929 cells
- (2008) Puja Chauhan et al. IMMUNOBIOLOGY
- Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients
- (2008) Paola Nisticò et al. INTERNATIONAL JOURNAL OF CANCER
- Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
- (2008) Mark E. Dudley et al. JOURNAL OF CLINICAL ONCOLOGY
- The Immune Adjuvant Properties of Front-line Carboplatin-Paclitaxel: A Randomized Phase 2 Study of Alternative Schedules of Intravenous Oregovomab Chemoimmunotherapy in Advanced Ovarian Cancer
- (2008) Patricia Braly et al. JOURNAL OF IMMUNOTHERAPY
- Chemotherapy and tumor immunity: an unexpected collaboration
- (2007) Leisha et al. Frontiers in Bioscience-Landmark
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now